Partnering to Build
West Africa's
Next Chapter.

RORO Strategic Holdings is a multi-sector investment holding company incorporated in Ghana, with a founding vision that dates to 2015 in the United States. The group wholly owns and operates four subsidiaries — Moovahub (logistics and luxury transport), Carevyon (digital healthcare), Rolyx Pharma (pharmaceuticals), and RORO Digital Solutions (technology and software) — all operating in Ghana and positioned for regional expansion across West Africa. The holding company provides strategic direction, governance oversight, capital allocation, and shared services to each subsidiary.

The group's founding vision was established in 2015 in the United States. RORO Technology was incorporated in Texas in 2019, providing the group's first formal legal entity. In 2026, RORO Holdings was incorporated in the United States and RORO Strategic Holdings was formally incorporated in Ghana, with all four subsidiaries established in the same year. This represents the culmination of a decade-long strategic build — not an opportunistic startup. The group's leadership team brings combined experience in technology, healthcare, logistics, and financial management.

RORO Strategic Holdings is led by Dr. Roland (Founder and Group Chairman), who holds overall strategic vision and investor relations responsibility. The executive team includes Nii Ashitey (Chief Operating Officer), responsible for day-to-day cross-subsidiary performance; Stephen Quansah (Chief Financial Officer), overseeing capital allocation, financial reporting, and treasury; and Manish Naruka (Chief Technology Officer), leading technology strategy, digital infrastructure, and RORO Digital Solutions.

The two entities are legally connected through a formally executed Technology Service Agreement. Under this agreement, RORO Holdings (USA) provides proprietary technology services, software infrastructure, and digital systems to RORO Strategic Holdings (Ghana). This is a contractually governed, arm's-length service relationship with documented obligations and transparent commercial terms — reflecting international best practice in cross-border group operations. Both entities operate with full legal clarity under their respective jurisdictions.

We engage with a range of serious capital partners: family offices, high-net-worth individuals, institutional investors, impact funds, diaspora investors, and strategic co-investors who share our long-term conviction about West Africa's growth potential. We are not seeking passive speculative capital — we are looking for partners aligned with our multi-year value creation horizon who see the strategic logic of building essential infrastructure businesses in a high-growth emerging market.

Yes. We are open to structured arrangements that provide direct exposure to a specific subsidiary — Moovahub, Carevyon, Rolyx Pharma, or RORO Digital Solutions — depending on the investor's sector interests and the subsidiary's capital requirements at the time. Each such arrangement is evaluated individually and structured to protect both parties' interests. Speak to our team to explore current subsidiary-level opportunities.

We evaluate investment structures on a case-by-case basis. There is no publicly stated minimum, as the appropriate structure depends heavily on the opportunity being discussed, the investor profile, and the timing. We welcome serious conversations at any scale and will be direct about whether an opportunity is a fit for both sides. The first step is always an introductory call.

Value creation at RORO comes from four sources: (1) operational improvement — building management depth and operational systems within each portfolio company; (2) revenue growth — expanding market share in high-growth Ghanaian and West African sectors; (3) structural value creation — developing companies to a stage where they attract premium valuations from strategic acquirers or capital markets; and (4) group synergies — the operational and commercial relationships between subsidiaries reduce costs and increase collective value. We build durable businesses, not short-cycle exits.

RORO Strategic Holdings operates under Ghanaian corporate law with governance standards modelled on international best practices. The group maintains board-level oversight of all subsidiaries, structured financial reporting, and management accountability frameworks. The Technology Service Agreement with RORO Holdings (USA) adds a layer of cross-border contractual governance. Each portfolio company maintains independent management leadership with clear reporting lines to the holding company. We prioritise financial transparency, audit readiness, and ethical governance as core institutional commitments.

All investment arrangements with RORO Strategic Holdings are governed by formal legal agreements drafted under the applicable laws of the relevant jurisdiction. We work with qualified legal counsel to structure arrangements that clearly define investor rights, reporting obligations, information rights, and exit mechanisms. We do not accept informal investment arrangements. Qualified investors who proceed through our engagement process will receive full legal documentation prior to any commitment.

RORO Strategic Holdings is incorporated and operates under Ghanaian corporate law, administered by the Registrar General's Department of Ghana. Its operating subsidiaries comply with sector-specific regulatory requirements: Rolyx Pharma operates under the Food and Drugs Authority of Ghana; Carevyon operates in compliance with applicable healthcare data and clinical standards; Moovahub operates under Ghana's transport and logistics regulatory framework; and RORO Digital Solutions operates under Ghana's National Information Technology Agency guidelines. RORO Holdings (USA) is incorporated under Texas state law.

Financial information is provided through our structured investor engagement process and is not disclosed publicly. Qualified investors who progress through our initial screening receive a formal information package that includes group-level financial overviews, portfolio company summaries, and projections. Detailed financial models, historical accounts, and five-year projections are available under a signed non-disclosure agreement to serious parties in active discussions.

We believe in transparent risk disclosure. Key considerations include: (1) Emerging market risk — Ghana's currency (GHS) and macroeconomic environment carry inherent volatility; (2) Early-stage company risk — our subsidiaries are in growth phase and may not yet be cash-flow positive across all operations; (3) Regulatory risk — sector-specific regulation in healthcare and pharmaceuticals may evolve; (4) Concentration risk — a significant portion of revenues is currently Ghana-dependent. We actively manage these risks through portfolio diversification, conservative capital planning, and our regional expansion strategy.

Primary operations are conducted in Ghanaian Cedis (GHS). The Technology Service Agreement with RORO Holdings (USA) creates a structured USD-denominated obligation, providing a natural cross-currency exposure mechanism. We are developing a formal currency risk management framework as part of our institutional readiness programme. Investors with USD exposure should factor GHS/USD exchange rate risk into their assessment.

The first step is to submit an investor enquiry through our contact page. Select 'Investment Enquiry' as the subject and include a brief description of your investment mandate or interest. We respond to all credible enquiries within 5 business days with a proposed next step — typically an introductory call with a senior member of the RORO leadership team. From there, the process moves to information sharing, structured discussion, and — for parties proceeding further — formal documentation.

Our investor engagement follows a structured four-stage process: (1) Initial enquiry and screening — we assess alignment of mandate and values; (2) Introductory call — a structured overview of the group, its subsidiaries, and current opportunities; (3) Information package — qualified investors receive our detailed group overview, financial summaries, and portfolio profiles under NDA; (4) Structured negotiation — for parties proceeding, we work collaboratively to structure an arrangement that serves both sides, covering terms, rights, reporting, and legal documentation.

Impact is embedded in our investment thesis, not appended to it. We operate in sectors that directly affect human welfare: healthcare access, medicine availability, logistics infrastructure, and technology democratisation. We measure impact through Ghanaian job creation, local talent development, import substitution (particularly in pharmaceuticals), and technology transfer. A formal ESG reporting framework aligned with international standards is currently under development as part of our institutional readiness roadmap and will be made available to investors ahead of our next capital raise.